Cantor Fitzgerald Issues Negative Outlook for ELDN Earnings

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for Eledon Pharmaceuticals in a note issued to investors on Monday, March 24th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will post earnings per share of ($1.23) for the year, down from their previous forecast of ($1.12). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share.

Separately, Guggenheim assumed coverage on Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They set a “buy” rating and a $9.00 price objective for the company.

Eledon Pharmaceuticals Price Performance

ELDN stock opened at $3.41 on Wednesday. The stock has a market capitalization of $204.20 million, a price-to-earnings ratio of -1.70 and a beta of 0.80. The company has a 50-day moving average of $4.13 and a two-hundred day moving average of $3.88. Eledon Pharmaceuticals has a 52-week low of $1.52 and a 52-week high of $5.54.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.32). During the same period last year, the company earned ($1.00) EPS.

Hedge Funds Weigh In On Eledon Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Tower Research Capital LLC TRC boosted its holdings in Eledon Pharmaceuticals by 418.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,944 shares of the company’s stock valued at $33,000 after purchasing an additional 6,412 shares during the period. Alpine Global Management LLC acquired a new position in shares of Eledon Pharmaceuticals during the fourth quarter valued at about $56,000. ADAR1 Capital Management LLC bought a new stake in shares of Eledon Pharmaceuticals in the fourth quarter valued at about $66,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Eledon Pharmaceuticals during the fourth quarter worth about $76,000. Finally, Virtu Financial LLC bought a new position in Eledon Pharmaceuticals during the fourth quarter valued at about $82,000. Institutional investors own 56.77% of the company’s stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).